CA-DIALPAD-INC.
17.6.2021 01:59:05 CEST | Business Wire | Press release
Dialpad Inc. , the industry leader in AI-powered communication and collaboration, today announced its platform integration with Microsoft Teams , a leading solution for team collaboration and engagement. Dialpad for Microsoft Teams is a cloud-native direct routing integration that seamlessly connects Dialpad’s enterprise-grade telephony features and award-winning Voice Intelligence (Vi™) capabilities into the Microsoft Teams native environment.
According to Microsoft’s Hybrid Work Trend Index , workers report that their productivity has either remained the same or increased over the past year. As work methods continue to evolve, Dialpad is at the forefront, creating better, smarter and more seamless communication experiences. With Dialpad direct routing at the heart of the integration, Microsoft Teams users have access to Dialpad’s global calling capabilities with PSTN connectivity in 49 countries in addition to sophisticated inbound and outbound calling features. Powered by automatic speech recognition, natural language processing and machine learning, Dialpad Vi provides Microsoft Teams users with real-time transcriptions, robust analytics, in-call coaching and intelligent conversation insights during every call.
“Today's technology and communications investments need to be in solutions that wholly integrate into how businesses work today, yet are flexible and scalable to evolve with them tomorrow,” said Craig Walker, Chief Executive Officer, Dialpad. “Today, more than 145 million people are using Microsoft Teams as their team collaboration tool, and nobody in the unified communications space does telephony services better than Dialpad. We’re excited to see the positive impact Dialpad direct routing will have on the calling experience for businesses using Microsoft Teams. With an open integration platform that natively extends and unifies business applications, Dialpad is delivering the best tools for teams to do their best work, both today and tomorrow.“
The coronavirus pandemic opened the business world’s eyes to new ways of working and ushered in the era of a hybrid work environment. Companies have implemented multiple tools to keep remote employees connected and engaged through video conferencing, messaging and chat tools, along with more traditional voice solutions. In addition to standard role responsibilities, employees face a new learning curve to integrate these tools into their workday. The management of multiple applications for a single, simple conversation can have detrimental effects on team productivity. Dialpad for Microsoft Teams centralizes and streamlines employee communications for more efficient, engaged, and ultimately, inclusive teams.
“The Dialpad integration with Microsoft Teams brings the best from both worlds — Microsoft Teams' collaboration and Dialpad's voice and real-time artificial intelligence capabilities,” said Ignacio Miranda, IT Vendor Manager, Gategroup. “An easy implementation and trouble-free user experience allows end-users to stay connected from anywhere, on any device, and enjoy a much better experience.”
From small and midsize businesses to large enterprises, organizations need a secure and reliable communications solution that enables seamless internal and external connections. Built for today’s modern hybrid workforce, Dialpad for Microsoft Teams provides a dynamic, flexible, highly scalable and reliable solution that is available on any device, at any time, anywhere in the world.
“Dialpad has focused on supporting highly distributed organizations and improving operational efficiency and productivity through its mobile-first, cloud-based unified communications and contact center solutions since its early days,” said Raul Castanon-Martinez, Senior Analyst, 451 Research, part of S&P Global Market Intelligence. “The integration with Microsoft Teams shows that the company continues to build and expand on this vision.”
See the Dialpad App Marketplace for more information on Dialpad for Microsoft Teams.
Additional Resources
- Check the latest blog for more details of Dialpad for Microsoft Teams.
- Learn why Dialpad is a Major Player in the IDC MarketScape: Worldwide UCaaS Service Providers for SMB and Enterprise 2021 Vendor Assessments
- Discover how Dialpad utilizes AI to unify UCaaS and CCaaS
About Dialpad
Dialpad is the leading cloud communications platform for AI-powered calling, conferencing and contact centers. Dialpad's proprietary, real-time Artificial Intelligence engine, Voice Intelligence (Vi™), helps businesses make smarter decisions by giving real-time insights on every call. Built on the Google Cloud Platform for unmatched security and reliability, Dialpad is easy to deploy, integrate and scale. Today, more than 70,000 of the world’s most innovative businesses use Dialpad and its seamless integrations with Google Workspace, Hubspot, Microsoft Office 365, Salesforce, Zendesk and others to allow every user to be more productive. Customers include T-Mobile, Twitter, WeWork, Uber, Stripe, Netflix, Motorola Solutions, Splunk and Domo. Dialpad is backed by the world’s leading investors including Amasia, Andreessen Horowitz, Felicis Ventures, GV, ICONIQ Capital, OMERS Growth Equity, Salesforce Ventures, Scale Ventures, Section 32, SoftBank Corp., T-Mobile Ventures and Work-Bench. Headquartered in the United States, Dialpad has offices in Australia/New Zealand, Brazil, Canada, India, Japan and the UK. Visit www.dialpad.com for more information and to request a demo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616006034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom